Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy

7th Edition of the AJCC Cancer Staging Manual: Stomach

(2010) Kay Washington   ANNALS OF SURGICAL ONCOLOGY

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation

(2010) Matthew H. G. Katz et al.   ANNALS OF SURGICAL ONCOLOGY

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY

[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer

(2010) D. Vallböhmer et al.   JOURNAL OF SURGICAL ONCOLOGY

Neoadjuvant therapy of locally advanced gastric cancer

(2010) James J. Mezhir et al.   JOURNAL OF SURGICAL ONCOLOGY

Gastric cancer

(2009) Henk H Hartgrink et al.   LANCET

Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer

(2008) Edip Ucar et al.   ADVANCES IN THERAPY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Usefulness of the Serum Carcinoembryonic Antigen Kinetic for Chemotherapy Monitoring in Patients With Unresectable Metastasis of Colorectal Cancer

(2008) Isabelle Iwanicki-Caron et al.   JOURNAL OF CLINICAL ONCOLOGY

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

(2008) Viviane Hess et al.   LANCET ONCOLOGY